GE HealthCare Technologies Inc. (NASDAQ:GEHC) Shares Sold by Aviso Wealth Management

Aviso Wealth Management decreased its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC) by 2.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,004 shares of the company’s stock after selling 522 shares during the quarter. Aviso Wealth Management’s holdings in GE HealthCare Technologies were worth $1,564,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. CoreFirst Bank & Trust purchased a new stake in GE HealthCare Technologies in the 4th quarter valued at about $25,000. Runnymede Capital Advisors Inc. purchased a new stake in GE HealthCare Technologies in the fourth quarter valued at approximately $28,000. Continuum Advisory LLC increased its position in GE HealthCare Technologies by 101.8% during the third quarter. Continuum Advisory LLC now owns 333 shares of the company’s stock worth $31,000 after purchasing an additional 168 shares during the last quarter. Bank of Jackson Hole Trust acquired a new position in shares of GE HealthCare Technologies in the 4th quarter valued at $32,000. Finally, OFI Invest Asset Management purchased a new stake in shares of GE HealthCare Technologies during the 4th quarter valued at $34,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on GEHC shares. The Goldman Sachs Group upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and lifted their target price for the company from $85.00 to $100.00 in a report on Tuesday, March 11th. Jefferies Financial Group raised GE HealthCare Technologies from a “hold” rating to a “buy” rating and lifted their price objective for the company from $95.00 to $103.00 in a research note on Wednesday, January 8th. Citigroup increased their target price on shares of GE HealthCare Technologies from $103.00 to $110.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Finally, Wells Fargo & Company lifted their price target on shares of GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, GE HealthCare Technologies has a consensus rating of “Moderate Buy” and a consensus target price of $98.75.

GE HealthCare Technologies Price Performance

Shares of NASDAQ GEHC opened at $82.46 on Wednesday. The company has a quick ratio of 0.83, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. GE HealthCare Technologies Inc. has a fifty-two week low of $74.51 and a fifty-two week high of $94.80. The business has a 50 day moving average price of $86.91 and a two-hundred day moving average price of $85.96. The firm has a market cap of $37.71 billion, a PE ratio of 19.04, a price-to-earnings-growth ratio of 3.19 and a beta of 1.13.

GE HealthCare Technologies (NASDAQ:GEHC) last issued its quarterly earnings results on Thursday, February 13th. The company reported $1.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.26 by $0.19. GE HealthCare Technologies had a net margin of 10.13% and a return on equity of 25.74%. The business had revenue of $5.32 billion during the quarter, compared to analyst estimates of $5.33 billion. Sell-side analysts expect that GE HealthCare Technologies Inc. will post 4.68 earnings per share for the current fiscal year.

GE HealthCare Technologies Company Profile

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.